| Hypertensive disease
Caduet vs Tribenzor
Side-by-side clinical, coverage, and cost comparison for hypertensive disease.Deep comparison between: Caduet vs Tribenzor with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTribenzor has a higher rate of injection site reactions vs Caduet based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Tribenzor but not Caduet, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Caduet
Tribenzor
At A Glance
Oral
Daily
Calcium channel blocker + HMG-CoA reductase inhibitor
Oral
Daily
ARB / CCB / thiazide diuretic
Indications
- Hypertensive disease
- Stable angina
- Angina Pectoris, Variant
- Coronary Artery Disease
- Hyperlipidemia
- Heterozygous familial hypercholesterolemia [HeFH]
- Homozygous familial hypercholesterolemia [HoFH]
- Hyperlipoproteinemia Type III
- Hypertriglyceridemia
- Diabetes Mellitus, Non-Insulin-Dependent
- Coronary heart disease
- Hypertensive disease
Dosing
Hypertensive disease Amlodipine 5 mg orally once daily (initial); max 10 mg once daily; start at 2.5 mg in elderly, fragile, small adult, pediatric (>6 years), or patients with hepatic insufficiency.
Stable angina, Angina Pectoris, Variant Amlodipine 5-10 mg orally once daily; most patients require 10 mg for adequate effect.
Coronary Artery Disease Amlodipine 5-10 mg orally once daily; majority of patients in clinical studies required 10 mg.
Hyperlipidemia, Hyperlipoproteinemia Type III, Hypertriglyceridemia, Diabetes Mellitus, Non-Insulin-Dependent, Coronary heart disease Atorvastatin 10-80 mg orally once daily; start at 40 mg if LDL-C reduction >45% is required.
Heterozygous familial hypercholesterolemia [HeFH] Atorvastatin 10-80 mg orally once daily in adults; 10-20 mg once daily in pediatric patients >=10 years.
Homozygous familial hypercholesterolemia [HoFH] Atorvastatin 10-80 mg orally once daily in adults and pediatric patients >=10 years; starting dose 10-20 mg once daily.
Hypertensive disease Once daily; dosage may be increased in 2-week intervals as needed; maximum recommended dose is 40/10/25 mg; dose selection should be individualized based on previous therapy.
Contraindications
- Acute liver failure or decompensated cirrhosis
- Hypersensitivity to amlodipine, atorvastatin, or any excipient in CADUET, including reactions such as anaphylaxis, angioneurotic edema, erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis
- Anuria
- Hypersensitivity to any component of Tribenzor or to other sulfonamide-derived drugs
- Co-administration of aliskiren in patients with diabetes
Adverse Reactions
Most common Edema, dizziness, flushing, palpitations, nasopharyngitis, arthralgia, diarrhea, pain in extremity, urinary tract infection, dyspepsia, nausea, musculoskeletal pain, muscle spasms, myalgia, insomnia, pharyngolaryngeal pain
Serious Myopathy, rhabdomyolysis, immune-mediated necrotizing myopathy, hepatic dysfunction, increases in HbA1c and fasting serum glucose
Postmarketing Rhabdomyolysis, myositis, fatal and non-fatal hepatic failure, anaphylaxis, tendon rupture, peripheral neuropathy, cognitive impairment, depression, interstitial lung disease, angioneurotic edema, Stevens-Johnson syndrome, toxic epidermal necrolysis, gynecomastia
Most common (>=2%) Dizziness, peripheral edema, headache, fatigue, nasopharyngitis, muscle spasms, nausea, upper respiratory tract infection, diarrhea, urinary tract infection, joint swelling
Postmarketing Angioedema, anaphylactic reactions, rhabdomyolysis, acute renal failure, sprue-like enteropathy, hyperkalemia, alopecia, pruritus, urticaria, gynecomastia, jaundice, hepatic enzyme elevations, extrapyramidal disorder, non-melanoma skin cancer (hydrochlorothiazide)
Pharmacology
CADUET combines amlodipine, a dihydropyridine calcium channel blocker that inhibits transmembrane calcium influx into vascular smooth muscle and cardiac muscle to reduce peripheral vascular resistance and blood pressure, with atorvastatin, a selective, competitive HMG-CoA reductase inhibitor that lowers plasma cholesterol by reducing cholesterol synthesis in the liver and increasing hepatic LDL receptor expression.
Triple-combination antihypertensive; olmesartan medoxomil selectively blocks angiotensin II AT1 receptors in vascular smooth muscle, amlodipine inhibits transmembrane calcium ion influx into vascular and cardiac smooth muscle, and hydrochlorothiazide promotes renal excretion of sodium and chloride to reduce intravascular volume.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Caduet
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (9/12)
Tribenzor
- Covered on 5 commercial plans
- PA (4/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Caduet
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Tribenzor
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Caduet
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (3/3)
Tribenzor
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Caduet.
No savings programs available for Tribenzor.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CaduetView full Caduet profile
TribenzorView full Tribenzor profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.